Evoke Pharma Inc.
| NASDAQ: EVOK | Healthcare / Drug Manufacturers / USA |
| 2.31 | -0.3100 | -11.83% | Vol 35.05K | 1Y Perf -57.61% |
| Mar 24th, 2023 16:00 DELAYED |
| BID | 2.25 | ASK | 2.40 | ||
| Open | 2.52 | Previous Close | 2.62 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 10.00 | Analyst Rating | — 0.00 | |
| Potential % | 332.90 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★ 46.03 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 6.08 | Earnings Rating | Neutral | |
| Market Cap | 7.72M | Earnings Date | 9th May 2023 | |
| Alpha | -0.01 | Standard Deviation | 0.27 | |
| Beta | 0.59 |
Today's Price Range 2.252.52 | 52W Range 1.3716.80 | 5 Year PE Ratio Range -2.40-3.80 |
Summary:
Sell
| Technical Indicators: | Sell |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -18.37% | ||
| 1 Month | -22.22% | ||
| 3 Months | -11.83% | ||
| 6 Months | 18.49% | ||
| 1 Year | -57.61% | ||
| 3 Years | -80.94% | ||
| 5 Years | -90.70% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -247.71 | |||
ROE last 12 Months | -169.02 | |||
ROA (5Y Avg) | -40.03 | |||
ROA last 12 Months | -69.53 | |||
ROC (5Y Avg) | -212.66 | |||
ROC last 12 Months | -74.35 | |||
Return on invested Capital Q | -16.62 | |||
Return on invested Capital Y | -16.83 | |||
Assets Turnover | 0.20 | |||
Receivables Turnover | 3.70 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -1.00 | ||||
| 1.69 | ||||
| 5.45 | ||||
| - | ||||
| -2.30 | ||||
| -2.04 | ||||
| 1.69 | ||||
| 1.66 | ||||
| 2.16M | ||||
| Forward PE | -23.58 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 6.90 | ||||
| 7.10 | ||||
| 0.48 | ||||
| 0.93 | ||||
| -15.20 | ||||
| Leverage Ratio | 2.50 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 84.70 | ||||
| -366.30 | ||||
| -366.30 | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 1.71M | ||||
| 0.51 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2022 | - | -0.60 | - |
| Q02 2022 | - | -0.71 | - |
| Q01 2022 | - | -0.07 | - |
| Q03 2021 | - | -0.06 | - |
| Q02 2021 | - | -0.07 | - |
| Q01 2021 | -0.06 | -0.08 | -33.33 |
| Q04 2020 | -0.04 | -0.09 | -125.00 |
| Q03 2020 | -0.10 | -0.08 | 20.00 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 6/2021 QR | -0.04 | 0.00 | - |
| 9/2021 QR | -0.02 | 0.00 | - |
| 12/2021 FY | -0.12 | 0.00 | - |
| 12/2021 FY | -0.12 | 0.00 | - |
| Next Report Date | 9th May 2023 |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 35.05K |
| Shares Outstanding | 3.34K |
| Shares Float | 196.21K |
| Trades Count | 170 |
| Dollar Volume | 83.29K |
| Avg. Volume | 24.35K |
| Avg. Weekly Volume | 20.50K |
| Avg. Monthly Volume | 16.36K |
| Avg. Quarterly Volume | 36.19K |
Evoke Pharma Inc. (NASDAQ: EVOK) stock closed at 2.31 per share at the end of the most recent trading day (a -11.83% change compared to the prior day closing price) with a volume of 35.05K shares and market capitalization of 7.72M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 4 people. Evoke Pharma Inc. CEO is David A. Gonyer.
The one-year performance of Evoke Pharma Inc. stock is -57.61%, while year-to-date (YTD) performance is -13.81%. EVOK stock has a five-year performance of -90.7%. Its 52-week range is between 1.3717 and 16.8, which gives EVOK stock a 52-week price range ratio of 6.08%
Evoke Pharma Inc. currently has a PE ratio of -1.00, a price-to-book (PB) ratio of 1.69, a price-to-sale (PS) ratio of 5.45, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -69.53%, a ROC of -74.35% and a ROE of -169.02%. The company’s profit margin is -%, its EBITDA margin is -366.30%, and its revenue ttm is $1.71 Million , which makes it $0.51 revenue per share.
Of the last four earnings reports from Evoke Pharma Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Evoke Pharma Inc.’s next earnings report date is 09th May 2023.
The consensus rating of Wall Street analysts for Evoke Pharma Inc. is — (0), with a target price of $10, which is +332.90% compared to the current price. The earnings rating for Evoke Pharma Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Evoke Pharma Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Evoke Pharma Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 20.26, ATR14 : 0.30, CCI20 : -189.24, Chaikin Money Flow : -0.08, MACD : -0.16, Money Flow Index : 58.23, ROC : -21.96, RSI : 35.21, STOCH (14,3) : 4.14, STOCH RSI : 0.00, UO : 29.51, Williams %R : -95.86), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Evoke Pharma Inc. in the last 12-months were:
Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
CEO: David A. Gonyer
Telephone: +1 858 345-1494
Address: 420 Stevens Avenue, Solana Beach 92075, CA, US
Number of employees: 4
